ACIP Recommendations: Diphtheria, Tetanus and Pertussis (DTaP/Tdap/Td) Vaccines

Key points

  • The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
  • These recommendations become official CDC policy once adopted by CDC's Director.
  • Learn about current and historical ACIP recommendations for Diphtheria, Tetanus and Pertussis (DTaP, Tdap, Td) vaccines.

Published in Morbidity and Mortality Weekly Report (MMWR)

Constrained U.S. Td supply, 2024‎

Production of one tetanus and diphtheria (Td) vaccine, TdVax™, has been discontinued. As a result, CDC anticipates that the supply of Td vaccine in the U.S. market will be constrained during 2024. CDC has developed guidance to help vaccination providers.

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

ARCHIVED Historical DTaP/Tdap/Td Vaccine Recommendations

For your convenience, these archived publications can be used for historical and research purposes.

Adolescents

Adults (under 65 years old)

Adults (65 years and older)

Infants and Young Children

Pregnancy Immunization